Regulus Therapeutics has entered into a collaboration with Biogen Idec to identify microRNAs as biomarkers for multiple sclerosis (MS). Biogen will make an investment in Regulus as well as upfront and milestone payments. The collaboration aims to identify microRNA biomarkers in the blood of patients with MS. Regulus believes that microRNA biomarkers can be used to select optimal patient segments in clinical trials to develop companion diagnostics and monitor disease progression.    “Utiliz...